Dana-Farber

Dana–Farber Cancer Institute is a comprehensive cancer treatment and research institution in Boston, Massachusetts. Dana-Farber is the founding member of Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School. Currently, Dana-Farber is ranked the #3 cancer hospital in the world. Two Nobel laureates in Physiology or Medicine are among its past and present faculty. Dana-Farber's research discoveries include the development of the highly successful Gleevec to treat chronic myeloid leukemia.

Read more in the app

FDA approves immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer, backed by Dana-Farber research - EurekAlert!

Diet influences survival after stage iii colon cancer, Dana-Farber study finds - EurekAlert!

Dana-Farber researchers identify interventions for breast and colorectal cancer that could redefine standard of care - EurekAlert!

Dana-Farber genomic score predicts progression to multiple myeloma - EurekAlert!

Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025 - EurekAlert!

Potential targeted therapy for pediatric brain cancer identified by Dana-Farber team - EurekAlert

Dana-Farber and Gustave Roussy announce 2025 - EurekAlert

Dana-Farber researchers uncover disparities in lived experiences for patients and physicians - EurekAlert

Dana-Farber nurses present research and evidence-based studies at 2024 Oncology Nursing Society Congress - EurekAlert

Dana-Farber Chief Scientific Officer, Kevin Haigis, PhD, elected as Fellow of the American Association for the ... - EurekAlert

Endometrial, lung, and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2024 - EurekAlert